Search Results
Found 1 results
510(k) Data Aggregation
(148 days)
APLIO 500/400/300 DIAGNOSTIC ULTRASOUND SYSTEM, V5.0
The Diaqnostic Ultrasound System Aplio 500 Model TUS-A500, Aplio 400 Model TUS-A400 And Aplio 300 Model TUS-A300 is indicated for the visualization of structures, and dynamic processes with the human body using ultrasound and to provide image information for diaqnosis in the following clinical applications: fetal, abdominal, intra-operative (abdominal), pediatric, small orqans, trans-vaqinal, trans-rectal, neonatal cephalic, adult cephalic, cardiac (both adult and pediatric), peripheral vascular, transesophaqeal, musculo-skeletal (both conventional and superficial) and laparoscopic.
The Aplio 500 Model TUS-A500, Aplio 400 Model TUS-A400 and Aplio 300 Model TUS-A300 are mobile diagnostic ultrasound systems. These systems are Track 3 devices that employ a wide array of probes including flat linear array, convex linear array, and sector array with frequency ranges between approximately 2 MHz to 12 MHz.
This document describes the 510(k) premarket notification for the Toshiba Medical Systems Corporation's Aplio 500/400/300 V5.0 Diagnostic Ultrasound System. The submission is a modification of a previously cleared device (K133761) and includes improvements to image quality, existing features (Needle Enhancement), and new features (Shear wave and Smart Navigation) along with four new transducers.
Here's an analysis of the acceptance criteria and study information provided:
1. Table of Acceptance Criteria and Reported Device Performance
The document does not explicitly present a table of quantitative acceptance criteria with reported device performance values. Instead, it describes "three studies" conducted to demonstrate that the new features perform as intended. The "reported device performance" is qualitative, indicating successful demonstration.
Acceptance Criterion (Implicit) | Reported Device Performance (Qualitative) |
---|---|
Improved Needle Visualization (Needle Enhancement Feature) | Confirmed that the subject device improves needle visualization. |
Accurate Shear Wave Speed and Elasticity Measurement | Confirmed that the subject device accurately measured the shear wave speed and elasticity of known targets within an elasticity phantom. |
Successful Needle Navigation (Smart Navigation Feature) | Demonstrated that the use of Smart Navigation successfully navigates needles to targets at various depths using a projected path displayed on the system. |
Conformance to Safety and Quality Standards | The device is designed and manufactured under the Quality System Regulations as outlined in 21 CFR § 820 and ISO 13485 Standards. This device is in conformance with the applicable parts of the IEC60601-1 (2005), IEC 60601-1-2:2007, IEC 60601-2-37 (2007), IEC 62304 (2006), AIUM RTD2-2004 Output Display and ISO 10993-1 standards. Software Documentation for a Moderate Level of Concern, per the FDA quidance document, "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices Document" issued on May 11, 2005, is also included as part of this submission. |
Functionality Similar to Predicate Device | The Aplio 500 Model TUS-A500 Version 5.0, Aplio 400 Model TUS-A400 Version 5.0 and Aplio 300 Model TUS-A300 Version 5.0 functions in a manner similar to and is intended for the same use as the predicate devices referenced within this submission. |
Image Quality Improvements (Overall) | Improvements upon image quality (qualitative statement, no specific metric provided). |
2. Sample Size Used for the Test Set and Data Provenance
The document states that "three studies were conducted," and the testing involved "bench testing" and "an elasticity phantom." It also mentions "targets at various depths." However, it does not specify numerical sample sizes for the test sets used in any of these studies.
The data provenance is from bench testing, implying controlled laboratory conditions rather than clinical human data. The country of origin of the data is not explicitly stated, but the submission is from "Toshiba Medical Systems Corporation, Shimoishigami Otawara-shi, Tochigi-ken, Japan 324-8550". It's likely the testing occurred in Japan or the US (as part of Toshiba America Medical Systems, Inc.). The studies are prospective in nature, as they were conducted to validate the new features of the device before market clearance.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts
The document does not specify the number of experts used or their qualifications for establishing ground truth for the bench testing.
For the shear wave study, "known targets within an elasticity phantom" were used. This indicates a physical phantom with pre-defined or known elastic properties, which serves as the ground truth. Therefore, expert input for ground truth establishment might have been less relevant or was built into the design of the phantom itself.
4. Adjudication Method for the Test Set
The document does not mention any adjudication method (e.g., 2+1, 3+1, none) for the test set results. The testing described appears to be objective performance evaluation based on physical measurements (e.g., accurately measuring shear wave speed) or functional confirmation (improving needle visualization, successful navigation).
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was Done
No, a Multi-Reader Multi-Case (MRMC) comparative effectiveness study was not mentioned in this document. The studies described are focused on the technical performance of new features rather than comparing human reader performance with and without AI assistance.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was Done
The performance of the "Needle Enhancement" and "Shear wave" features likely involves standalone measurements by the algorithm/system, as they are inherent imaging modes or measurement capabilities. For example, "accurately measured the shear wave speed and elasticity of known targets within an elasticity phantom" implies an algorithm-only measurement. The "Smart Navigation" feature "successfully navigates needles to targets" where the system displays a "projected path," which could be interpreted as the algorithm providing guidance that a human then follows. While not explicitly stated as "standalone evaluation," the nature of these tests suggests measuring the direct output of the device's enhanced functionalities.
7. The Type of Ground Truth Used
The types of ground truth used for the specific performance tests are:
- Needle Enhancement: Implicitly, the visibility of a physical needle in an ultrasound image. The ground truth for "improved visualization" would be a qualitative assessment, possibly against a baseline or a known ideal.
- Shear Wave: "Known targets within an elasticity phantom." This indicates a physical phantom with established mechanical properties (e.g., known elasticity values).
- Smart Navigation: "Targets at various depths" with a "projected path displayed on the system." The ground truth here would be the physical location of the targets and the actual path the needle takes compared to the projected path.
8. The Sample Size for the Training Set
The document does not provide any information regarding the sample size for a training set. This is not uncommon for 510(k) submissions, especially for ultrasound systems where "AI" might refer to advanced image processing algorithms rather than deep learning models requiring large training datasets. The focus here is on the functional performance validation of hardware and software features.
9. How the Ground Truth for the Training Set Was Established
Since no training set is mentioned (see point 8), there is no information on how ground truth for a training set was established.
Ask a specific question about this device
Page 1 of 1